1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-1342.
2. He S, Lin B, Chu V, Hu Z, Hu X, Xiao J, Wang AQ, Schweitzer CJ, Li Q, Imamura M, Hiraga N, Southall N, Ferrer M, Zheng W, Chayama K, Marugan JJ, Liang TJ. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med. 2015;7:282-249.
3. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873.
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-362.
5. Zaman AA, Karim R, Khan ST, Khan SA. Frequecny of hbsag and anti-hcv in asymptomatic healthy blood donors at hmc, Peshawar. KJMS. 2014;1:155-158.
6. Hill AM, Roberts T, Amorosa V, Pourmand K, Matthews G, Cooke G, Khan H, Main J, Brown A, Peter JA, Nelson DR. Can HCV Antigen Testing Replace HCV RNA PCR Analysis, for Diagnosis and Monitoring of Treatment for Hepatitis C?. In Hepatology 2015;07030-5774.
7. Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012;12:e6894.
8. Debing Y, Jochmans D, Neyts J. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol. 2013;3:217-224.
9. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A. 2012;109:6205-6210.
10. WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization; 2014.
11. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Felix J, Ferraz ML, Ferreira PR, Frankova S, Garcia-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimaraes Pessoa M, Hezode C, Hofer H, Husa P, Idilman R, Kaberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lazaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Starkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;21 Suppl 1:5-33.
12. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107-115.
13. Dhiman RK. Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?. J Clin Exp Hepatol. 2014;4:85-86.
14. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74-81.
15. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol. 2012;26:487-503.
16. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:41-46.
17. Chinchai T, Labout J, Noppornpanth S, Theamboonlers A, Haagmans BL, Osterhaus AD, Poovorawan Y. Comparative study of different methods to genotype hepatitis C virus type 6 variants. J Virol Methods. 2003;109:195-201.
18. Abdelwahab SF, Hashem M, Galal I, Sobhy M, Abdel-Ghaffar TS, Galal G, Mikhail N, El-Kamary SS, Waked I, Strickland GT. Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infection. J Clin Virol. 2013;57:24-28.
19. Al Naamani K, Al Sinani S, Deschenes M. Epidemiology and treatment of hepatitis C genotypes 5 and 6. Can J Gastroenterol. 2013;27:e8-12.
20. Trinks J, Gadano A, Argibay P. Evolving trends in the hepatitis C virus molecular epidemiology studies: from the viral sequences to the human genome. Epidemiology Research International. 2012.
21. Afridi SQ, Zahid MN, Shabbir MZ, Hussain Z, Mukhtar N, Tipu MY, Akhtar F, Yaqub T. Prevalence of HCV genotypes in district Mardan. Virol J. 2013;10:90.
22. Umar S, Waheed Y, Ashraf M. Hepatitis B and hepatitis C viruses: a review of viral genomes, viral induced host immune responses, genotypic distributions and worldwide epidemiology. Asian Pac J Trop Biomed. 2014;4:88-96.
23. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol. 2000;32:209-217.
24. Rasheed A, Ullah S, Naeem S, Zubair M, Ahmad W, Hussains Z. Occurrence of HCV genotypes in different age groups of patients from Lahore, Pakistan. ALS. 2014;2:89-95.
25. Afridi SQ, Ali MM, Awan F, Zahid MN, Afridi IQ, Afridi SQ, Yaqub T. Molecular epidemiology and viral load of HCV in different regions of Punjab, Pakistan. Virol J. 2014;11:24.
26. Butt S, Idrees M, Akbar H, ur Rehman I, Awan Z, Afzal S, Hussain A, Shahid M, Manzoor S, Rafique S. The changing epidemiology pattern and frequency distribution of hepatitis C virus in Pakistan. Infect Genet Evol. 2010;10:595-600.
27. Muhammad U, Bilal M. Hepatitis C, a mega menace: a Pakistani Perspective. Journal of Pioneering Medical Sciences. 2012;2:68.
28. Furuta A, Salam KA, Akimitsu N, Tanaka J, Tani H, Yamashita A, Moriishi K, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Noda N. Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase. J Enzyme Inhib Med Chem. 2014;29:223-229.
29. Akhtar J, Qamar MU, Hakeem A, Waheed A, Sarwar F, Anwar J. Sero-prevalence of HBV and HCV in Tuberculous Patients at Sheikh Zayed Hospital Rahim Yar Khan, Pakistan. Biomedica. 2013;29:69-72.
30. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis. 2011;15:515-536.
31. Asad M, Ahmed F, Zafar H, Farman S. Frequency and determinants of Hepatitis B and C virus in general population of Farash Town, Islamabad. Pak J Med Sci. 2015;31:1394-1398.
32. Khalid A, Zahid M, Aslam Z, Bilal M, Haider A. Sero-Epidemiology of Hepatitis B and C Virus in Rural Population of Tehsil Samundri, District Faisalabad, Pakistan. International Journal of Virology and Molecular Biology. 2015;4:19-22.
33. Rafaqat B, Ahmed M, Aziz A, Sultan N. Hepatitis B and C Virus Infection in Surgical Practice. Journal of Surgery Pakistan. 2015;20:64-67.
34. Hussain A, Mumtaz HM, Aslam MS, Abbas Z. Seroprevalence of transfusion based transmissible infections among clinically healthy donors in the community of Multan Pakistan. J Inf Mo Bio. 2015;3:47-51.
35. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M; InC3 Study Group. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59:109-120.
36. Zubair AK, Shafiq M, Shahab F. Frequency and risk factors of hepatitis b&c in afghan patients presenting to tertiary care hospital in peshawar. Pakistan Armed Forces Medical Journal. 2015;65:686-689.
37. Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, Freilich B, Zamparo J, Brown K, Dimitrova D, Kumar M, Manion D, Heath-Chiozzi M, Wolf R, Hughes E, Muir AJ, Hernandez AF.Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 2015;62:409-416.
38. Rasheed A, Ullah S, Naeem S, Zubair M, Ahmad W, Hussain Z. Occurrence of HCV genotypes in different age groups of patients from Lahore, Pakistan. Advancements in Life Sciences. 2014;1:89-95.
39. Khan J, Shafiq M, Mushtaq S, Ayaz S, Ullah R, Naser M, AbdEI-Salam A, Fouad H, Wasim MA. Seropositivity and coinfection of hepatitis B and C among patients seeking hospital care in Islamabad, Pakistan. BioMed. 2014.
40. Abdul Majeed A, Majeed S, Majeed S, Javed H. Hepatitis C Virus Infection in Pregnant Women in Lahore, Pakistan: An Analytical Cross Sectional Study. International Journal of Agriculture Biology 2014;16:160-164.
41. Irfan SM, Uddin J, Zaheer HA, Sultan S, Baig A. Trends in transfusion transmitted infections among replacement blood donors in karachi, Pakistan. Turk J Haematol. 2013;30:163-167.
42. Khan A, Tareen AM, Ikram A, Rahman H, Wadood A, Qasim M, Khan K. Prevalence of HCV among the young male blood donors of Quetta region of Balochistan, Pakistan. Virol J. 2013;10:83.
43. Munir M, Shams S, Lodhi MA, Parveen Z, Ullah N. Prevalence of Hepatitis B in the Students, and Employees of Abdul Wali Khan University Mardan Shankar Campus. Pakhtunkhwa J Life Sci. 2013;3:120-129.
44. Mengal MA, Abbas F, Mengal MA, Shafee M, Babar S, Mengal MA, Atique MS. Passive surveillance of anti-hepatitis C virus antibodies in human subjects of four medical units of Balochistan, Pakistan. International Journal of Agriculture and Biology. 2012;14:585-589.
45. Ali S, Ahmad A, Khan RS, Khan S, Hamayun M, Khan SA, Iqbal A, Khan AA, Wadood A, Ur Rahman T, Baig AH. Genotyping of HCV RNA reveals that 3a is the most prevalent genotype in mardan, pakistan. Adv Virol. 2014;2014:606201.
46. Sohail U, Satapathy SK. Diagnosis and management of alcoholic hepatitis. Clin Liver Dis. 2012;16:717-736.
47. Akbar H, Idrees M, Butt S, Awan Z, Sabar MF, Rehaman Iu, Hussain A, Saleem S. High baseline interleukine-8 level is an independent risk factor for the achievement of sustained virological response in chronic HCV patients. Infect Genet Evol. 2011;11:1301-5130.
48. Bacon BR, Khalid O. New therapies for hepatitis C virus infection. Mo Med. 2011;108:255-259.
49. Ali A, Ahmed H, Idrees M. Molecular epidemiology of Hepatitis C virus genotypes in Khyber Pakhtoonkhaw of Pakistan. Virol J. 2010;7:203.
50. Aziz S, Khanani R, Noorulain W, Rajper J. Frequency of hepatitis B and C in rural and periurban Sindh. J Pak Med Assoc. 2010;60:853-857.
51. Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol. 2009;9:5.
52. Afzal MS, Anjum S, Zaidi NU. Effect of Functional Interleukin-10 Polymorphism on Pegylated Interferon-α Plus Ribavirin Therapy Response in Chronic Hepatitis C Virus Patients Infected With 3a Genotype in Pakistani Population. Hepat Mon. 2013;13:e10274.
53. Waqar M, Khan AU, Rehman HU, Idrees M, Wasim M, Ali A, Niaz Z, Ismail Z, Rehman MU, Tariq M, Shah M, Murtaza BN. Determination of hepatitis C virus genotypes circulating in different districts of Punjab (Pakistan). Eur J Gastroenterol Hepatol. 2014;26:59-64.
54. Ali MK, Light JA, Barhyte DY, Sasaki TM, Currier CB Jr, Grandas O, Fowlkes D. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation. 1998;66:1694-1697.
55. Butt AA, Khan UA, Shaikh OS, McMahon D, Dorey-Stein Z, Tsevat J, Lo Re V. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials. 2009;10:25-32.
56. Ramezani A, Amirmoezi R, Volk JE, Aghakhani A, Zarinfar N, McFarland W, Banifazl M, Mostafavi E, Eslamifar A, Sofian M. HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. AIDS Care. 2014;26:1122-1126.
57. Khubaib B, Saleem S, Idrees M, Afzal S, Wasim M. The genotype CC of IL‐28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV‐infected Pakistani patients. J Dig Dis. 2015;16:293-298.
58. Athar MA, Xu Y, Xie X, Xu Z, Ahmad V, Hayder Z, Hussain SS, Liao Y, Li Q. Rapid detection of HCV genotyping 1a, 1b, 2a, 3a, 3b and 6a in a single reaction using two-melting temperature codes by a real-time PCR-based assay. J Virol Methods. 2015;222:85-90.
59. Bakhshipour A, Sargolzaie N, Kiani M, Barazesh F. Hepatitis C Virus Genotypes in Patients Referred to Educational Hospitals in Zahedan (2009-2013). Int J Infect. 2016;3:e34666.
60. Mustafa GM, Larry D, Petersen JR, Elferink CJ. Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients. World J Hepatol. 2015;7:1312-2134.
61. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R, Lau JY. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35:201-207.
62. Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis. 2008;8:69.
63. Ahmad W, Ijaz B, Javed FT, Jahan S, Shahid I, Khan FM, Hassan S. HCV genotype distribution and possible transmission risks in Lahore, Pakistan. World J Gastroenterol. 2010;16:4321-4328.
64. Khan S, Attaullah S, Ayaz S, Niaz Khan S, Shams S, Ali I, Bilal M, Siraj S. Molecular epidemiology of hcv among health care workers of khyber pakhtunkhwa. Virol J. 2011;8:105.
65. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology. 2005;42:310-316.
66. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. N Engl J Med. 2014;370:1869-1871.
67. Basit A, Rahim K, Ahmad I, Shafiq M, Mushtaq S, Shaheen H, Khan I. Prevalence of Hepatitis B and C Infection in Pakistan. J Inf Mol Biol. 2014;2:35-38.
68. Junejo SA, Khan NA, Lodhi AA. Prevalence of hepatitis B and C infection in patients admitted at tertiary eye care centre: A hospital based study. Pak J Med Sci. 2009;25:597-600.
69. Hashmi A, Saleem K, Soomro JA. Prevalence and factors associated with hepatitis C virus seropositivity in female individuals in islamabad, pakistan. Int J Prev Med. 2010;1:252-256.
70. Janjua NZ, Hamza HB, Islam M, Tirmizi SF, Siddiqui A, Jafri W, Hamid S. Health care risk factors among women and personal behaviours among men explain the high prevalence of hepatitis C virus infection in Karachi, Pakistan. J Viral Hepat. 2010;17:317-326.
71. el-Danasoury AS, Eissa DG, Abdo RM, Elalfy MS. Red blood cell alloimmunization in transfusion-dependent Egyptian patients with thalassemia in a limited donor exposure program. Transfusion. 2012;52:43-47.
72. Aslam M, Aslam J. Seroprevalence of the antibody to hepatitis C in select groups in the Punjab region of Pakistan. J Clin Gastroenterol. 2001;33:407-411.
73. Paintsil E, Binka M, Patel A, Lindenbach BD, Heimer R. Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission. J Infect Dis. 2014;209:1205-1211.
74. Aziz H, Raza A, Murtaza S, Waheed Y, Khalid A, Irfan J, Samra Z, Athar MA. Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis. Int J Infect Dis. 2013;17:e247-253.
75. Pawlotsky JM. Hepatitis C treatment: The data flood goes on-An update from the liver meeting 2014. Gastroenterology. 2015;148:468-479.
76. Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schreter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarcuska P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Puri P, Razavi H.The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm-volume 2. J Viral Hepat. 2015;22 Suppl 1:26-45.
77. Zaheer HA, Saeed U, Waheed Y, Karimi S, Waheed U. Prevalence and trends of hepatitis B, hepatitis C and human immunodeficiency viruses among blood donors in Islamabad, Pakistan 2005-2013. J Blood Disorders Transf. 2014;5:1000217.
78. Naveed S, Qamar F, Zainab S, Sarwar G. A Survey Study on awareness of Hepatitis C in different groups. World J Pharml Sci. 2014;2:2321-2331.
79. Aziz H, Raza A, Murtaza S, Waheed Y, Khalid A, Irfan J, Samra Z, Athar MA. Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis. Int J Infect Dis. 2013;17:e247-253.
80. Bhawani Y, Raghava Rao P, Sudhakar V. Seroprevalence of transfusion transmissible infections among blood donors in a tertiary care hospital of Andhra Pradesh. Biol Med. 2010;2:45-48.
81. Gyawali S, Rathore DS, Shankar PR, Maskey M, Vikash KK. Injection practices in Nepal: health policymakers’ perceptions. BMC Int Health Hum Rights. 2014;14:21.
82. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ. 1999;77:789-800.
83. John S, Miller R. Radical common sense: community provision of injectable contraception in Africa. Critical Issues in Reproductive Health. 2014;33:265-284.
84. Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Muir D, McClure MO. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS. 2009;23:89-93.
85. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Thomas D, Fix AD, Strickland GT, Anwar W, Sallam I. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 2000;32:111-115.
86. Zia A, Ullah I, Ali S, Zia M, Mathew S, Fatima K, Raza A, Qadri I. Prevalent risk factors of HCV transmission in health care workers (HCWS) in Pakistan. Int J Pharm Pharm Sci. 2015;11:365-370.
87. Imran M, Rafique H, Khan A, Malik T. A model of bi-mode transmission dynamics of hepatitis C with optimal control. Theory Biosci. 2014;133:91-109.
88. Safi SZ, Waheed Y, Sadat J, Solat-Ul-Islam, Salahuddin S, Saeed U, Ashraf M. Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. Asian Pac J Trop Biomed. 2012;2:532-536.
89. Kuo I, Ul-Hasan S, Galai N, Thomas DL, Zafar T, Ahmed MA, Strathdee SA. High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J. 2006;3:26.
90. Khan A, Tareen AM, Ikram A, Rahman H, Wadood A, Qasim M, Khan K. Prevalence of HCV among the young male blood donors of Quetta region of Balochistan, Pakistan. Virol J. 2013;10:83.
91. Khan NU, Ali I, Ahmad NU, Iqbal A, Rehman LU, Munir I, Rehman MU, Khan S, Ali S, Siddique L, Swati ZA. Prevalence of active HCV infection among the blood donors of Khyber Pakhtunkwa and FATA region of Pakistan and evaluation of the screening tests for anti-HCV. Virol J. 2011;8:154.
92. Khanani MR, Somani M, Khan S, Naseeb S, Ali SH. Prevalence of single, double, and triple infections of HIV, HCV and HBV among the MSM community in Pakistan. J Infect. 2010;61:507-509.
93. Hafeez-ud-din, Siddiqui TS, Lahrasab W, Sharif MA. Prevalence of hepatitis B and C in healthy adult males of paramilitary personnel in Punjab. J Ayub Med Coll Abbottabad. 2012;24:138-140.
94. Akhtar M, KhanMA, Ijaz T, Majeed S. Hepatitis C Virus Infection in Pregnant Women in Lahore, Pakistan: An Analytical Cross Sectional Study. International Journal of Agriculture Biology. 2014;16:160164.
95. Mathew S, Fatima K, Fatmi MQ, Archunan G, Ilyas M, Begum N, Azhar E, Damanhouri G, Qadri I. Computational docking study of p7 Ion channel from HCV genotype 3 and genotype 4 and its interaction with natural compounds. PLoS One. 2015;10:e0126510.
96. Rafiq N, Younossi ZM. Younossi. Effects of weight loss on nonalcoholic fatty liver disease. Seminars in liver disease. Semin Liver Dis. 2008;28:427-433.
97. Perumpail RB, Wong RJ, Ha LD, Pham EA, Wang U, Luong H, Kumari R, Daugherty TJ, Higgins JP, Younossi ZM, Kim WR, Glenn JS, Ahmed A. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis. 2015;17:275-278.
98. Tunio SA, Bano S, Laghari ZA, Ali W, Shamim H, Afreen. U Seroprevalence of Hepatitis B and Hepatitis C among blood donors in Hyderabad, Pakistan. Gomal Journal of Medical Sciences. 2014;11:220-223.
99. Pfaender S, Heyden J, Friesland M, Ciesek S, Ejaz A, Steinmann J, Steinmann J, Malarski A, Stoiber H, Tsiavaliaris G, Bader W, Jahreis G, Pietschmann T, Steinmann E. Inactivation of hepatitis C virus infectivity by human breast milk. J Infect Dis. 2013;208:1943-1952.
100. Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish RG, Busch MP, Reingold AL, Alter MJ. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57:881-889.
101. Bibi S, Dars S, Ashfaq S, Ara Qazi R, Akhund S. Seroprevalence and risk factors for hepatitis C virus (HCV) infection in pregnant women attending public sector tertiary care hospital in Hyderabad Sindh. Pak J Med Sci. 2013;29:505-508.
102. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, du Cros P. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis. 2012;54:1465-1472.
103. Chemaitelly H, Abu-Raddad LJ, Miller FD. An apparent lack of epidemiologic association between hepatitis C virus knowledge and the prevalence of hepatitis C infection in a national survey in Egypt. PLoS One. 2013;8:e69803.
104. Dhiman RK, Chawla YK. Minimal hepatic encephalopathy. Indian J Gastroenterol. 2009;28:5-16.
105. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-1444.
106. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, Crespo J, Andrade R, Martnez-Bauer E, Perez R, Testillano M, Planas R, Sola R, Garcia-Bengoechea M, Garcia-Samaniego J, Munoz-Sanchez M, Moreno-Otero R; TeraViC-4 Study Group. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451-460.
107. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509-516.e1.
108. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329-337.
109. Lewis H, Cunningham M, Foster G. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26:471-485.
110. Cheng G, Peng B, Corsa A, Yu M, Nash M, Lee YJ, Xu Y, Kirschberg T, Tian Y, Taylor J, Link JO, Delaney W. 1172 antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885. Journal of Hepatology. 2012;56:S464.